Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.

As shown, in the PP cohort of the current GAPP-MDD study, compared to TAU, patients in the guided-care arm had greater HAM-D17-measured symptom improvement (27.6% versus 22.7%; p = 0.274), higher response rate (30.3% versus 22.7%; p = 0.262), and higher remission rate (15.7% versus 8.3%; p = 0.131), although comparisons did not reach statistical significance.

also in 111,027 other papers